Reputation Doesn't Expand Your Trade Mark: What Self Care v Allergan Means for Australian Brand Owners

Reputation Doesn't Expand Your Trade Mark: What Self Care v Allergan Means for Australian Brand Owners

When the High Court of Australia speaks unanimously on trade mark law, practitioners and brand owners take note. In Self Care IP Holdings Pty Ltd v Allergan Australia Pty Ltd [2023] HCA 8, a five-judge bench delivered a landmark decision that reshaped how Australian trade mark infringement is assessed — and delivered a clear message: the fame of your brand does not automatically widen the scope of your legal protection.

Background: BOTOX, Skincare, and a Competitor's Claims

Allergan is the company behind BOTOX, the globally recognised injectable treatment for reducing facial wrinkles. In Australia, Allergan holds the BOTOX trade mark registered in class 5 for pharmaceutical preparations. It also holds a defensive trade mark registration for BOTOX in class 3 — covering cosmetic products such as anti-ageing and anti-wrinkle creams — despite not actually selling any class 3 products under that name. This defensive registration exists purely to prevent others from registering confusingly similar marks in that space, a mechanism provided under section 185 of the Trade Marks Act 1995 (Cth).

Self Care IP Holdings sells cosmetic skincare products under the FREEZEFRAME brand. Two products were at issue in the proceedings:

• Inhibox — packaging described the product as an "instant Botox® alternative"

• Protox — a product whose very name was alleged to be deceptively similar to BOTOX

Allergan argued both products infringed its trade mark rights and that Self Care's marketing made misleading representations under the Australian Consumer Law (ACL).

Key Legal Issues

1. Was "instant Botox® alternative" Trade Mark Use?

Trade mark infringement under section 120(1) of the Act requires that the alleged infringer use a sign as a trade mark — that is, as a badge of origin indicating who produced or supplied the goods. The High Court held that the phrase "instant Botox® alternative" on Self Care's Inhibox packaging was not trade mark use. The reference to BOTOX was descriptive and comparative — it communicated the product's purpose to consumers rather than suggesting that Self Care was the origin of goods associated with the BOTOX brand. Because it was not used as a badge of origin, there was no infringement on this basis.

2. Was PROTOX Deceptively Similar to BOTOX?

The central test for deceptive similarity under Australian law asks whether a person of ordinary intelligence with imperfect recollection, encountering both marks separately, would be likely to be deceived or confused. The High Court found that PROTOX was not deceptively similar to BOTOX. The difference in the first letter — P versus B — created a sufficiently distinct visual and aural impression. Despite the shared "OTOX" suffix, a consumer familiar with BOTOX would not be likely to mistake PROTOX for it or assume a connection.

3. The Critical Rule: Reputation Is Irrelevant to Deceptive Similarity

This is the decision's most significant contribution to Australian trade mark law. The Full Federal Court below had allowed Allergan's strong reputation in BOTOX to influence the deceptive similarity analysis — effectively reasoning that because BOTOX is so famous, consumers are more likely to associate similar marks with it. The High Court emphatically rejected this approach.

Under section 120(1), deceptive similarity is assessed objectively: the comparison is between the registered mark and the allegedly infringing sign, assessed in the abstract, without reference to how famous the registered mark may be. Reputation does not expand the scope of trade mark protection. A powerful brand like BOTOX gets the same legal comparison test as a modest regional brand.

4. Defensive Trade Marks and the Infringement Threshold

The Court also considered Allergan's section 185 defensive registration of BOTOX in class 3. Defensive trade marks have a unique feature: they can be infringed without the requirement for the defendant's use to be "use as a trade mark." However, because neither product was found to be deceptively similar to BOTOX in any event, this route to infringement was also closed.

5. Misleading Conduct Under the ACL

While Allergan largely lost on trade mark infringement, it succeeded on a different front. The Court found that Self Care's marketing of Inhibox implied the product had effects lasting as long as a genuine Botox injection — a representation that was misleading. This was a breach of section 18 of the ACL. The lesson: even where trade mark infringement fails, misleading claims about product efficacy or performance can still create substantial liability.

Strategic Takeaways for Brand Owners

• Fame does not mean wider protection. Under Australian law, the deceptive similarity test is the same regardless of how famous your mark is. If you want broader legal protection, you need broader registrations — including defensive trade marks under section 185.

• Defensive trade mark registrations matter. Section 185 allows well-known brands to register defensively in classes where they do not trade, precisely to prevent others from registering similar marks. This is a tool that only applies once a mark is sufficiently well-known that the Registrar accepts the defensive application.

• Comparative advertising carries risk, but not always trade mark infringement risk. Saying your product is "an alternative to X" is descriptive and comparative — it is not trade mark use. But be careful about implied claims regarding performance or efficacy, which can still breach the ACL.

• The ACL is an independent risk. Trade mark infringement and misleading conduct are separate causes of action. You can lose on trade marks and still face liability under the ACL — and vice versa.

• Conduct thorough clearance searches. Even marks that seem superficially similar to famous brands may survive a deceptive similarity challenge. Objective comparison of the marks — not the fame of either — drives the outcome.

Conclusion

Self Care v Allergan is essential reading for anyone involved in Australian trade mark law. It confirms that brand owners cannot use the fame of their marks as a legal lever to sweep up lookalike competitors. Protection must be earned through careful registration strategy, and the limits of that protection are defined by the marks actually registered — not the brand's commercial reputation in the marketplace.

If you are a brand owner seeking to protect your trade marks, or a business navigating claims of infringement, getting specialist advice early can make the difference between a successful outcome and an expensive dispute.

Contact Stellar IP Law to speak with a trade mark specialist about your brand protection strategy.